

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome/Cognome

SERGIO ABRIGNANI

Indirizzo

UNIVERSITÀ DEGLI STUDI DI MILANO- UNIMI
INGM ISTITUTO NAZIONALE GENETICA MOLECOLARE "ROMEO ED ENRICA INVERNIZZI"
PADIGLIONE INVERNIZZI - VIA FRANCESCO SFORZA, 35 – 20122 MILANO

Telefono Ufficio

02 0066 0328

Fax Ufficio

02 0066 0216

E-mail

abrignani@ingm.org ; sergio.abrignani@unimi.it

CODICE FISCALE

BRGSRG58H03E974U

Nazionalità

Italiana

Data di nascita

03 GIUGNO 1958

Luogo di nascita

MARSALA (TP)

ORCID ID

0000-0002-0794-3285

ESPERIENZA LAVORATIVA

- Date (da - a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego

01 Giugno 2015

Università degli Studi di Milano – Via Festa del Perdono, 7 – 20122 Milano

Università

Professore ordinario di Patologia Generale - Dipartimento di Scienze cliniche e di comunità (DISCCO)

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego

01 Gennaio 2006

FONDAZIONE INGM Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi"
Centro di Ricerca Biomedica finalizzato alla scoperta e allo sviluppo iniziale di nuovi mezzi diagnostici, nuove terapie e vaccini.

Direttore Scientifico

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego

1999-2005

Chiron Corporation, Emeryville (CA), USA

Farmaceutica

Vice Presidente, Dipartimento di ricerca e sviluppo

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego

1994 – 2000

Università di Siena

Scuola di specializzazione in Gastroenterologia, Facoltà di Medicina
Professore a contratto

- Date (da – a) Aprile 1993 – 1999
- Nome e indirizzo del datore di lavoro Centro Ricerche Chiron - Siena
 - Tipo di azienda o settore Farmaceutica
 - Tipo di impiego Direttore del Dipartimento di Immunologia e Virologia
- Date (da – a) 1990 – Marzo 1992
- Nome e indirizzo del datore di lavoro Ciba-Geigy, Basilea, Svizzera
 - Tipo di azienda o settore
 - Tipo di impiego Responsabile del Laboratorio Vaccini presso il Dipartimento di Allergia/Immunologia
- Date (da – a) 1988 – 1989
- Nome e indirizzo del datore di lavoro Ciba-Geigy, Basilea, Svizzera
 - Tipo di azienda o settore
 - Tipo di impiego Ricercatore presso il Dipartimento di Allergia/Immunologia
- Date (da – a) 1986 – 1987
- Nome e indirizzo del datore di lavoro Sandoz, Basilea, Svizzera
 - Tipo di azienda o settore
 - Tipo di impiego Ricercatore presso il Dipartimento di Ricerca Preclinica
- Date (da – a) 1983 – 1985
- Nome e indirizzo del datore di lavoro Istituto di Patologia Generale, Facoltà di Medicina, Università di Palermo
 - Tipo di azienda o settore
 - Tipo di impiego Assistente Medico

PREMI E RICONOSCIMENTI

- Date (da–a) 2011-2016
ERC Advanced Grant
- Date (da–a) 2004
Medaglia d'oro al merito della Sanità Pubblica per i suoi studi sul virus dell'epatite C

ISTRUZIONE E FORMAZIONE

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)

1986

Facoltà di Medicina dell'Università di Palermo

Specializzazione in Patologia Generale, votazione 70/70 con lode

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)

1982

Facoltà di Medicina dell'Università di Padova

Laurea in medicina, votazione 110/110 con lode

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)

1976

Liceo Classico "Giovanni XXIII", Marsala (TP)

Maturità Classica

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA

ITALIANO

ALTRE LINGUE

Autovalutazione

Livello europeo (*)

Inglese

Tedesco

Comprensione

Ascolto

Lettura

Parlato

Interazione

Produzione orale

Scritto

C2 Utente avanzato C2 Utente avanzato C2 Utente avanzato C2 Utente avanzato C2 Utente avanzato

B1 Utente autonomo B1 Utente autonomo B1 Utente autonomo B1 Utente autonomo B1 Utente autonomo

(*) Quadro comune europeo di riferimento per le lingue

ULTERIORI INFORMAZIONI

“Reviewer” di articoli sulle seguenti riviste scientifiche:

European Journal of Immunology
EMBO Journal
Hepatology
Immunity
International Immunology
Journal of Clinical Investigation
Journal of Hepatology
Journal of Immunology
Nature
Nature Immunology
Nature Medicine
Science

Publicazioni di maggiore rilievo (solo pubblicazioni con Impact Factor > 3)

(*) indica che SA è il “corresponding author”

H index secondo GS: **57**

Total citations secondo GS: **12548**

	Tutte	Dal 2011
Citazioni	12548	4609
H index	57	35
i10-index	109	85

1. De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C1, Bonnal RJP, Provasi E, Sarnicola M, Panzeri I, Moro M, Crosti M, Mazzara S, Vaira V, Bosari S, Palleschi A, Santambrogio L, Bovo G, Zucchini N, Totis M, Gianotti L, Cesana G, Perego R, Maroni N, Pisani Ceretti A, Opocher E, De Francesco R, Geginat J, Stunnenberg HG, **Abrignani S***, Pagani M. “Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells” *Immunity*. 2016 Nov 15;45(5):1135-1147
2. Stunnenberg HG; International Human Epigenome Consortium, Hirst M. “The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery Cell”. 2016 Nov 17;167(5):1145-1149. doi: 10.1016/j.cell.2016.11.007.
3. Ranzani V, Arrigoni A, Rossetti G, Panzeri I, **Abrignani S**, Bonnal RJ, Pagani M. „Next-Generation Sequencing Analysis of Long Noncoding RNAs in CD4+ T Cell Differentiation” *Methods Mol Biol*. 2017;1514:173-185.
4. Geginat J, Paroni M, Kastirr I, Larghi P, Pagani M, **Abrignani S**. „Reverse plasticity: TGF- β and IL-6 induce Th1-to-Th17-cell transdifferentiation in the gut”. *Eur J Immunol*. 2016 Oct;46(10):2306-2310. doi: 10.1002/eji.201646618.
5. Arrigoni A, Ranzani V, Rossetti G, Panzeri I, **Abrignani S**, Bonnal RJ, Pagani M. „Analysis RNA-seq and Noncoding RNA” *Methods Mol Biol*. 2016;1480:125-35.

6. Paroni M, Magarotto A, Tartari S, Nizzoli G, Larghi P, Ercoli G, Gianelli U, Pagani M, Elli L, **Abrignani S**, Conte D, Geginat, Caprioli F. "Uncontrolled IL-17 Production by Intraepithelial Lymphocytes in a Case of non-IPEX Autoimmune Enteropathy." *Clin Transl Gastroenterol*. 2016 Jul 14;7(7):e182. doi: 10.1038/ctg.2016.41.
7. Nizzoli G, Larghi P, Paroni M, Crosti MC, Moro M, Neddermann P, Caprioli F, Pagani M, De Francesco R, **Abrignani S**, Geginat J. "IL-10 promotes homeostatic proliferation of human CD8+ memory T cells and, when produced by CD1c+ DCs, shapes naive CD8+ T-cell priming" *Eur J Immunol*. 2016 Jul;46(7):1622-32.
8. Geginat J, Larghi P, Paroni M, Nizzoli G, Penatti A, Pagani M, Gagliani N, Meroni P, **Abrignani S**, Flavell RA. "The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer" *Cytokine Growth Factor Rev*. 2016 Aug;30:87-93.
9. de Candia P, Torri A, Fedeli M, Viganò V, Carpi D, Gorletta T, Casorati G, Pagani M, Dellabona P, **Abrignani S**. "The circulating microRNome demonstrates distinct lymphocyte subset-dependent signatures". *Eur J Immunol*. 2015 Dec 7. doi: 10.1002/eji.201545787.
10. Geginat J, Nizzoli G, Paroni M, Maglie S, Larghi P, Pascolo S, **Abrignani S**. "Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets". *Front Immunol*. 2015 Oct 13;6:527.
11. Cheroni C, Donnici L, Aghemo A, Balistreri F, Bianco A, Zanoni V, Pagani M, Soffredini R, D'Ambrosio R, Rumi MG, Colombo M, **Abrignani S**, Neddermann P, De Francesco R. "Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity." *PLoS One*. 2015 Sep 25;10(9):e0138546.
12. Bonnal RJ, Ranzani V, Arrigoni A, Curti S, Panzeri I, Guarini P, **Abrignani S**, Rossetti G, Pagani M. "De novo transcriptome profiling of highly purified human lymphocytes primary cells." *Sci Data*. 2015 Sep 29;2:150051.
13. Mazzara S, Sinisi A, Cardaci A, Rossi RL, Muratori L, **Abrignani S**, Bombaci M. "Two of Them Do It Better: Novel Serum Biomarkers Improve Autoimmune Hepatitis Diagnosis". *PLoS One*. 2015 Sep 16;10(9):e0137927
14. Kastirr I, Crosti MC, Maglie S, Paroni M, Steckel B, Moro M, Pagani M, **Abrignani S**, Geginat J "Signal Strength and Metabolic Requirements Control Cytokine-Induced Th17 Differentiation of Uncommitted Human T Cells" *J Immunol*. 2015 Oct 15;195(8):3617-27.
15. Marabita F, de Candia P, Torri A, Tegnér J, **Abrignani S**, Rossi RL. "Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR." *Brief Bioinform*. 2015 Aug 3. pii: bbv056. Epub 2015 Aug 3.
16. Facciotti F, Gagliani N, Häringer B, Alfen JS, Penatti A, Maglie S, Paroni M, Iseppon A, Moro M, Crosti MC, Stölzel K, Romagnani C, Moroni G, Ingegnoli F, Torretta S, Pignataro L, Annoni A, Russo F, Pagani M, **Abrignani S**, Meroni P, Flavell R, Geginat J. "IL-10-producing forkhead box protein 3-negative regulatory T cells inhibit B-cell responses and are involved in systemic lupus erythematosus". *J Allergy Clin Immunol*. 2015 Aug 25. pii: S0091-6749(15)00999-9. doi: 10.1016/j.jaci.2015.06.044. Epub 2015 Aug 25.

17. Bonnal R JP, Rossi RL, Carpi D, Ranzani V, **Abrignani S**, Pagani M. "miRiadne: a web tool for consistent integration of miRNA nomenclature" *Nucleic Acids Res.* 2015 Jul 1;43(W1):W487-92.
18. Ranzani V, Rossetti G, Panzeri I, Arrigoni A, Bonnal RJP, Curti S, Provasi E, Sugliano E, De Francesco R, Geginat J, Bodega B, **Abrignani S***, Pagani M. "LincRNAs landscape in human lymphocytes highlights regulation of T cell differentiation by linc-MAF-4". *Nat Immunol.* 2015 Mar;16(3):318-25.
19. Geginat J, Paroni M, Maglie S, Alfen JS, Kastirr I, Gruarin P, DeSimone M, Pagani M, **Abrignani S***. "Plasticity of human CD4 T cell subsets". *Front. Immunol.* 2014, 5:630.
20. Reghellin V, Donnici L, Fenu S, Berno V, Calabrese V, Pagani M, **Abrignani S**, Peri F, De Francesco R, Neddermann P. "NS5A inhibitors impair NS5A- PI4KIII α complex formation and cause a decrease of PI4P and cholesterol levels in HCV-associated membranes." *Antimicrob Agents Chemother.* 2014 Dec;58(12):7128-40.
21. Kastirr I, Maglie S, Paroni M, Alfen JS, Nizzoli G, Sugliano E, Crosti MC, Moro M, Steckel B, Steinfeld S, Stölzel K, Romagnani C, Botti F, Caprioli F, Pagani M, **Abrignani S**, Geginat J "IL-21 Is a Central Memory T Cell-Associated Cytokine That Inhibits the Generation of Pathogenic Th1/17 Effector Cells" *J Immunol.* 2014 Oct 1;193(7):3322-31.
22. Dellabona P, **Abrignani S**, Casorati G "iNKT cell help to B cells: a cooperative job between innate and adaptive immune responses". *European Journal of Immunology*, 2014; 44(8):2230-7.
23. Zingaretti C, De Francesco R, **Abrignani S***, "Why it is so difficult to develop an HCV preventive vaccine?". *Clinical Microbiology and Infection*, 2014 May;20 Suppl 5:103-9.
24. de Candia P, Torri A, Pagani M, **Abrignani S*** "Serum microRNAs as biomarkers of human lymphocyte activation in health and disease" *Frontiers in Immunology*, 2013; 10:5-43.
25. de Candia P, Torri A, Gorletta T, Fedeli M, Bulgheroni E, Cheroni C, Marabita F, Crosti M, Moro M, Pariani E, Romanò L, Esposito S, Mosca F, Rossetti G, Rossi RL, Geginat J, Casorati G, Dellabona P, Pagani M, **Abrignani S***, "Intracellular Modulation, Extracellular Disposal and Serum Increase of MiR-150 Mark Lymphocyte Activation". *PLoS One.* 2013 Sep 26;8(9).
26. Geginat J, Paroni M, Facciotti F, Gruarin P, Kastirr I, Caprioli F, Pagani M, **Abrignani S***, "The CD4-centered universe of human T cell subsets". *Semin Immunol.* 2013; 25(4):252-62.
27. Nizzoli G, Krietsch J, Weick A, Steinfeld S, Facciotti F, Gruarin P, Bianco A, Steckel B, Moro M, Crosti M, Romagnani C, Stoelzel K, Torretta S, Pignataro L, Scheibenbogen C, Neddermann P, De Francesco R, **Abrignani S***, Geginat J., "Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses". *Blood*, 2013; 122(6): 932-42.
28. Pagani M, Rossetti G, Panzeri I, de Candia P, Bonnal RJ, Rossi RL, Geginat J, **Abrignani S***. "Role of microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation". *Immunol Rev.* 2013; 253(1):82-96.

29. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, **Abrignani S**, Tyrrell DL, Houghton M., "A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans". *PLoS One* 2013; 8(3):e59776.
30. Delang L, Neyts J, Vliegen I, **Abrignani S**, Neddermann P, De Francesco R., "Hepatitis C virus-specific directly acting antiviral drugs". *Curr Top Microbiol Immunol*. 2013; 369:289-320.
31. Caprioli F, Bosè F, Rossi RL, Petti L, Viganò C, Ciafardini C, Raeli L, Basilisco G, Ferrero S, Pagani M, Conte D, Altomare G, Monteleone G, **Abrignani S**, Reali E., "Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy". *Inflamm Bowel Dis*. 2013; 19(4):729-739.
32. Zingaretti C, Arigo' M, Cardaci A, Moro M, Crosti M, Sinisi A, Sugliano E, Cheroni C, Marabita F, Nogarotto R, Bonnal RJ, Marcatili P, Marconi M, Zignego A, Muratori P, Invernizzi P, Colombatto P, Brunetto M, Bonino F, De Francesco R, Geginat J, Pagani M, Muratori L, **Abrignani S***, Bombaci M, "Identification of new autoantigens by protein array indicates a role for IL4 neutralization in Autoimmune Hepatitis". *Mol Cell Proteomics*. 2012; 11(12):1885-97.
33. Moro M, Crosti M, Creo P, Gallina P, Curti S, Sugliano E, Scavelli R, Cattaneo D, Canidio E, Marconi M, Rebullia P, Sarmientos P, Viale G, Pagani M, **Abrignani S***. "Identification of new hematopoietic cell subsets with a polyclonal antibody library specific for neglected proteins". *PLoS One* 2012; 7(4):e34395.
34. Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, **Abrignani S**, De Francesco R, Colombo M. "IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B". *Hepatology* 2012; 57(3):890-6.
35. Novellino L, Rossi RL, Bonino F, Cavallone D, **Abrignani S**, Pagani M, Brunetto MR. "Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs". *PLoS One* 2012; 7(3), e31952.
36. Bianco A, Reghellin V, Donnici L, Fenu S, Alvarez R, Baruffa C, Peri F, Pagani M, **Abrignani S**, Neddermann P, De Francesco R. "Metabolism of Phosphatidylinositol 4-Kinase III α -Dependent PI4P Is Subverted by HCV and Is Targeted by a 4-Anilino Quinazoline with Antiviral Activity". *PLoS Pathog* 2012; 8(3):e1002576.
37. Tonti E, Fedeli M, Napolitano A, Iannacone M, Von Andrian UH, Guidotti LG, **Abrignani S**, Casorati G, Dellabona P. "Follicular Helper NKT Cells Induce Limited B Cell Responses and Germinal Center Formation in the Absence of CD4+ T Cell Help". *J. Immunol*. 2012; 188(7):3217-22.
38. Stamatakis Z, Coates S, **Abrignani S**, Houghton M, McKeating JA. "Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains". *J Infect Dis*. 2011; 204(5):811-3.
39. Grifantini R, Pagani M, Pierleoni A, Grandi A, Parri M, Campagnoli S, Pileri P, Cattaneo D, Canidio E, Pontillo A, De Camilli E, Bresciani A, Marinoni F, Pedrazzoli E, Nogarotto R, **Abrignani S**, Viale G, Sarmientos P, Grandi G. "A novel polyclonal

antibody library for expression profiling of poorly characterized, membrane and secreted human proteins" *J. Proteomics* 2011; 75(2): 532-47.

40. Rossi RL, Rossetti G, Wenandy L, Curti S, Ripamonti A, Bonnal RJP, Sciarretta BR, Moro M, Crosti MC, Guarin P, Maglie S, Marabita F, Mascheroni D, Parente V, Comelli M, Trabucchi E, De Francesco R, Geginat J, **Abrignani S***, Pagani M. "Distinct microRNA signatures in human lymphocyte subsets and enforcement of T cell naïve state by miR-125b". *Nature Immunol.* 2011; 12, 796-803.
41. Marabita, F., Aghemo, A., De Nicola, S., Rumi, M. G., Cheroni, C., Scavelli, R., Crimi, M., Soffredini, R., **Abrignani, S.**, De Francesco, R., and Colombo, M. "Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection". *Hepatology* 2011. 54(4), 1127-1134.
42. Bosè F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, Caprioli F, Scavelli R, Altomare G, Geginat J, **Abrignani S**, Reali E. "Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues". *Clin Immunol.* 2011; 139(2):164-76.
43. L. Rivino, P. Guarin, B. Häring, S. Steinfeld, L. Lozza, E. Sugliano, A. Weick, D. Jarrossay, A. Kuehl, C. Loddenkemper, **S. Abrignani**, F. Sallusto, A. Lanzavecchia and J. Geginat "CCR6 is expressed on an IL-10 producing, auto-reactive memory T cell population with context-dependent regulatory function" *J. Exp. Med.* 2010; 207: 565-577.
44. Ray R, Meyer K, Banerjee A, Basu A, Coates S, **Abrignani S**, Houghton M, Frey SE, Belshe RB. "Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins". *J Infect Dis.* 2010; 202(6): 862-6.
45. Frey SE, Houghton M, Coates S, **Abrignani S**, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. "Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults". *Vaccine* 2010; 28(38): 6367-73.
46. **Abrignani S***, Tonti E, Casorati G, Dellabona P. "B cell helper assays". *Methods Mol Biol.* 2009; 514: 15-26.
47. Tonti E, Galli G, Malzone C, **Abrignani S**, Casorati G, Dellabona P. "NKT-cell help to B lymphocytes can occur independently of cognate interaction". *Blood* 2009; 113(2): 370-6.
48. Serra A, Nuti S, Tavarini S, Sammiceli C, Rosa D, Saletti G, Soldaini E, **Abrignani S***, Wack A. "Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function". *J Immunol.* 2008; 181(1): 174-85.
49. Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, Fong YL, Chien D, **Abrignani S**, Balfe P, Rice CM, McKeating JA, Houghton M. "Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies". *Vaccine.* 2007; 25(45): 7773-84.
50. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, Maione D, Volpini G, Finco O, Nuti S, Tavarini S, Dellabona P, Rappuoli R, Casorati G & **S Abrignani***. "Invariant NKT cells sustain specific B cell responses and memory". *PNAS.* 2007; 104: 3984-9.

51. Brazzoli M, Crotta S, Bianchi A, Bagnoli F, Monaghan P, Wileman T, **Abrignani S** & M Merola. "Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line". *J Hepatol.* 2006; 46: 53-59.
52. Vajdy M, Selby M, Medina-Selby A, Coit D, Hall J, Tandeske L, Chien D, Hu C, Rosa D, Singh M, Kazzaz J, Nguyen S, Coates S, Ng P, **Abrignani S**, Lin YL, Houghton M & O'Hagan DT. "Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses". *J Gen Virol.* 2006; 87: 2253-2262.
53. Crotta S, Ronconi V, Ulivieri C, Baldari CT, Valiente NM, **Abrignani S** & Wack A. "Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells". *Eur J Immunol.* 2006; 36: 919-929.
54. Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G & **S Abrignani***. "Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte e disorders". *PNAS.* 2005; 102: 18544-18549.
55. Kong WP, Xu L, Stadler K, Ulmer JB, **Abrignani S**, Rappuoli R & GJ Nabel. "Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization". *J Virol.* 2005; 79: 13915-13923.
56. Houghton M & **S Abrignani***. "Prospects for a vaccine against the hepatitis C virus". *Nature* 2005; 436: 961-966.
57. Capo S, Nuti S, Scarselli M, Tavarini S, Montigiani S, Mori E, Finco O, **Abrignani S**, Grandi G & G Bensi. "Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8+ T cell epitopes recognized by infection-primed T cells". *Vaccine* 2005; 23: 5028-5037.
58. Mazzocca A, Cappadona Sciammetta S, Carloni V, Cosmi L, Annunziato F, Harada T, **Abrignani S** & M Pinzani. "Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells". *J. Biol. Chem.* 2005; 280: 11329-11339.
59. Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F, Ciccorossi P, Zorat F, Pozzato G, Comar C, **Abrignani S*** & A Wack. "Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic Hepatitis C patients and healthy donors". *J. Hepatol.* 2005; 42: 61-67.
60. Brazzoli M, Helenius A, Foug SK, Houghton M, **Abrignani S** and M. Merola. "Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells". *Virology* 2005; 332: 438-453.
61. Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, Brunetto M, Yen TS, Houghton M, Pileri P & **Abrignani S***. "Association of hepatitis C virus envelope proteins with exosomes". *Eur. J. Immunol.* 2004; 34: 2834-2842.
62. Song HC, Seo MY, Stadler K, Yoo BJ, Choo QL, Coates SR, Uematsu Y, Harada T, Greer CE, Polo JM, Pileri P, Eickmann M, Rappuoli R, **Abrignani S**, Houghton M & JH Han. "Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein". *J. Virol.* 2004; 78: 10328-10335.

63. De Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, Nuti S, Colombo M, Callea F, Porcelli SA, Panina-Bordignon P, **Abrignani S**, Casorati G & P Dellabona. "Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis". *J. Immunol.* 2004; 173: 1417-1425.
64. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, **Abrignani S**, Mondelli MU & V Barnaba. "Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection". *J. Clin. Invest.* 2004; 113: 963-972.
65. Stadler K, Masignani V, Eickmann M, Becker S, **Abrignani S**, Klenk HD & R Rappuoli. "SARS--beginning to understand a new virus". *Nat. Rev. Microbiol.* 2003; 1: 209-218.
66. Eickmann M, Becker S, Klenk HD, Doerr HW, Stadler K, Censini S, Guidotti S, Masignani V, Scarselli M, Mora M, Donati C, Han JH, Song HC, **Abrignani S**, Covacci A & R Rappuoli. "Phylogeny of the SARS coronavirus". *Science.* 2003; 302: 1504-1505.
67. Galli G, Nuti S, Tavarini S, Galli Stampino L, De Lalla C, Casorati G, Dellabona P & **S Abrignani***. "Innate immune responses support adaptive immunity: NKT cells induce B cell activation". *Vaccine.* 2003; 21: S2/ 48-54.
68. Galli G, Nuti S, Tavarini S, Galli Stampino L, De Lalla C, Casorati G, Dellabona P & **S Abrignani***. "CD1d-Restricted Help To B Cells By Human Invariant NKT Lymphocytes". *J. Exp. Med.* 2003; 197: 1051-1057.
69. Soldaini E, Wack A, D'Oro U, Nuti S, Olivieri C, Baldari CT & **S Abrignani***. "T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck". *Eur. J. Immunol.* 2003; 33: 455-464.
70. Seo MY, **Abrignani S**, Houghton M & H Han. "Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7". *J Virol.* 2003; 77: 810-812.
71. Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, **Abrignani S** & Y Uematsu. "Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection". *Virology.* 2002; 304: 187-196.
72. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filipponi F, Brunetto RM, Bonino F, **Abrignani S*** & N Valiante. "Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein". *J Exp Med.* 2002; 195: 35-41.
73. Falugi F, Petracca R, Mariani M, Luzzi E, Mancianti S, Carinci V, Melli ML, Finco O, Wack A, Di Tommaso A, De Magistris MT, Costantino P, Del Giudice G, **Abrignani S**, Rappuoli R & G Grandi. "Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to *Haemophilus influenzae* type b oligosaccharide: a model for new conjugate vaccines". *Eur J Immunol.* 2001; 31: 3816-38240.
74. Merola M, Brazzoli M, Cocchiarella F, Heile JM, Helenius A, Weiner AJ, Houghton M & **S Abrignani***. "Folding of hepatitis C virus E1 glycoprotein in a cell-free system". *J Virol.* 2001; 75: 11205-11217.

75. Burioni R, Bugli F, Mancini N, Rosa D, Di Campi C, Moroncini G, Manzin A, **Abrignani S**, Varaldo PE, Clementi M & G Fadda. "Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs". *Virology*. 2001; 288: 29-35, .
76. Agrati C, D'Offizi G, Narciso P, **Abrignani S**, Ippolito G, Colizzi V & F Poccia. "Vdelta1 T lymphocytes expressing a Th1 phenotype are the major gammadelta T cell subset infiltrating the liver of HCV-infected persons". *Mol.Med*. 2001. 7: 11-19.
77. Prezzi C, Casciaro MA, Francavilla V, Schiaffella E, Finocchi L, Chircu LV, Bruno G, Sette A, **Abrignani S** & V Barnaba. "Virus-specific CD8⁺ T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection". *Eur. J. Immunol*. 2001; 31: 894-906.
78. Kitadokoro K, Bordo D, Galli G, Petracca R, Falugi F, **Abrignani S**, Grandi G & M Bolognesi. "CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs". *EMBO J*. 2001; 15: 12-18.
79. Wack A, Soldaini E, Tseng CT, Nuti S, Klimpel GR & **S Abrignani***. "Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells". *Eur J Immunol*. 2001 ; 31:166-175.
80. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, **Abrignani S** & SK Fong. "Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes". *J Virol*. 2000; 74: 10407-10416.
81. Allander T, Drakenberg K, Beyene A, Rosa D, **Abrignani S**, Houghton M, Widell A, Grillner L & MA Persson. "Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81". *J Gen Virol*. 2000 ; 81: 2451-2459.
82. D'Andrea A, Goux D, De Lalla C, Koezuka Y, Montagna D, Moretta A, Dellabona P, Casorati G & **S Abrignani***. "Neonatal invariant Valpha24+ NKT lymphocytes are activated memory cells". *Eur J Immunol*.2000 ; 30: 1544-1550.
83. Heile JM, Fong YL, Rosa D, Berger K, Saletti G, Campagnoli S, Bensi G, Capo S, Coates S, Crawford K, Dong C, Wining M, Baker G, Cousens L, Chien D, Ng P, Archangel P, Grandi G, Houghton M & **S Abrignani***. "Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates". *J Virol*. 2000; 74: 6885-6892.
84. Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, Burgio V, Di Stasio E, Giardina B, Houghton M, **Abrignani S** & G Grandi. "Structure-function analysis of hepatitis C virus envelope-CD81 binding". *J. of Virol*. 2000; 74: 4824-4830.
85. Valiante N, D'Andrea A, Crotta S, Lechner F, Klenerman O, Nuti S, Wack A & **S Abrignani***. "Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C". *Immunol. Rev*. 2000; 174: 77-89.
86. **Abrignani S***, Houghton M & HH Hsu "Perspectives for a vaccine against hepatitis C virus". *J Hepatol*.1999, 31: 259-263.

87. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, Chircu ML, Sidney J, Southwood S, **Abrignani S**, Sette A & V Barnaba. "Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors". *J Immunol.* 1999; 162: 6681-6689.
88. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G & **S Abrignani***. "Binding of hepatitis C Virus to CD81". *Science.* 1998; 282: 938-941.
89. Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, Barnaba V, & **S Abrignani***. "Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for V α 24+ T-cells and rapid elimination of effector cells by apoptosis". *Eur. J. Imm.* 1998; 28: 3456-3467.
90. Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt C, Kiyosawa K, Aizaki H, Matsuura Y, Houghton M, **Abrignani S*** & T Miyamura. "High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C". *Hepatology.* 1998; 28: 1117-1120.
91. Habersetzer F, Fournillier A, Dubuisson J, Rosa D, **Abrignani S**, Wychowski C, Nakano I, Trepo C, Desgranges C, Inchauspe G. "Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties". *Virology.* 1998; 249: 32-41.
92. Burioni R, Plaisant P, Manzin A, Rosa D, Delli Carri V, Bugli F, Solforosi L, **Abrignani S**, Varaldo PE, Fadda G & M Clementi. "Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments". *Hepatology.* 1998; 28: 810-814.
93. **Abrignani S**. "Antigen-independent activation of resting T-cells in the liver of patients with chronic hepatitis". *Dev. Biol. Stand.* 1998; 92: 191-194.
94. Grifantini R, Finco O, Bartolini E, Draghi M, Del Giudice G, Kochen C, Thomas A, **Abrignani S** & G Grandi. "Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid". *Eur. J. Imm.* 1998; 28: 1225-1232.
95. **Abrignani S***. "Bystander activation by cytokines of intrahepatic T cells in chronic viral hepatitis". *Seminars in Liver Disease* 1997; 17: 319-322.
96. **Abrignani S***. "Immune responses throughout HCV infection: HCV from the immune system point of view". *Springer Seminars in Immunopathology.* 1997; 19: 47-56.
97. Finco O, Nuti S, Mangiavacchi L, Aiuti A, Forte P, Fantoni A, van der Putten H & **S Abrignani***. "Induction of CD4+ T-cell depletion in mice doubly transgenic for HIV-gp120 and human CD4". *Eur. J. Imm.* 1997; 27: 1319-1324.
98. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, Weiner A, Lau J, Choo Q, Chien D, Pileri P, Houghton M & **S Abrignani***. "A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein-E2 binding to target cells". *PNAS* 1996; 93: 1759-1763.
99. Di Tommaso A, Saletti G, Pizza M, Rappuoli R, Dougan G, **Abrignani S**, Douce G & M De Magistris. "Induction of antigen-specific antibodies in vaginal secretions using a

- non-toxic mutant of LT as a mucosal adjuvant". *Infect. Immun.* 1996; 64: 974-979.
100. Unutmaz D, Baldoni F & **S Abrignani***. "Human naive T cells activated by cytokines differentiate into a split phenotype with functional features intermediate between naive and memory cells". *Int. Immunol.* 1995; 9: 1417-1424.
101. **Abrignani S**. "Cellular immune reactions against hepatitis C core in chronic hepatitis C". *Gastroenterology* 1995; 108: 1957-1958.
102. Di Tommaso A, Xiang Z, Bugnoli M, Figura N, Bayeli P, Rappuoli R, **Abrignani S** & MT De Magistris. "Helicobacter Pylori specific CD4+ T cell clones from peripheral blood and gastric biopsies". *Infect. Immun.* 1995; 63:1102-1106.
103. Unutmaz D, Pileri P & **S Abrignani***. "Antigen-independent activation of naive and memory resting T cells by a cytokine combination". *J. Exp. Med.* 1994; 180: 1159-1164.
104. Di Tommaso A, De Magistris MT, Bugnoli M, Marsili I, Rappuoli R & **S Abrignani***. "Formaldehyde-treatment of proteins can constrain presentation to T-cells by limiting antigen processing". *Infect. Immun.* 1994; 62: 1830-1834.
105. Minutello M, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Bonino F, Brunetto M & **S Abrignani***. "Compartmentalization of T-lymphocytes to the site of disease: Intrahepatic CD4+ T-cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis". *J. Exp. Med.* 1993; 178: 17-25.
106. Botarelli P, Brunetto M, Minutello M, Calvo P, Unutmaz D, Weiner AJ, Choo QL, Shuster J, Kuo G, Bonino F, Houghton M & **S Abrignani***. "T lymphocyte response to hepatitis C virus in different clinical courses of infection". *Gastroenterology* 1993; 104: 580-587.
107. Minutello M, Unutmaz D, Brunetto M, Kuo G, Bonino F, Houghton M & **S Abrignani***. "T-cell response to HCV in peripheral blood and liver and its correlation with protection and pathogenicity". *J. Hepatol.* 1992; 17, S1: 5-6.
108. Botarelli P, Houlden B A, Haigwood NL, Servis K, Montagna D & **S Abrignani***. "N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes". *J Immunol.* 1991 147(9):3128-32.
109. **Abrignani S***, Montagna D, Jeannot M, Wintsch J, Haigwood NL, Shuster JR, Steimer KS, Cruchoad A & T Staehelin. "Priming of CD4+ T cells specific for conserved regions of HIV-gp120 in humans immunized with a recombinant envelope protein". *Proc Natl Acad Sci USA.* 1990 87(16):6136-40.
110. Lanzavecchia A, Roosnek E, Gregory T, Berman P & **S Abrignani***. "T cells can present antigens such as HIV gp120 targeted to their own surface molecules". *Nature.* 1988 334(6182):530-2.
111. Lanzavecchia A, **Abrignani S**, Scheidegger D, Obrist R, Doerken B & G Moldenhauer. "Antibodies as antigen: the use of monoclonal antibodies to focus human T cells against selected targets". *J Exp Med.* 1988; 167(2):345-52.

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.
Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

SERGIO ABRIGNANI



Milano, 24 novembre 2016